MGC Pharmaceuticals Ltd (ASX: MXC) announced the launch of a new proprietary reasonable prescription medicine line which will be known as Mercury Pharma, particularly for Australia and New Zealand.
At present, the purchase order for MP100 has already been received for more than 2,000 units which would be delivered in January and February 2020. It will be having a direct impact on the Q1 2020 revenues.
At AEDT 1:47 PM, MXC shares are trading at $0.033, up 3.125% from its previous close.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.